News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,669 Results
Type
Article (14035)
Company Profile (103)
Press Release (253531)
Section
Business (88679)
Career Advice (466)
Deals (15432)
Drug Delivery (67)
Drug Development (36848)
Employer Resources (49)
FDA (6313)
Job Trends (6222)
News (151230)
Policy (14093)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (4)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (451)
Adcomms (6)
Allergies (32)
Alliances (23387)
ALS (36)
Alzheimer's disease (385)
Antibody-drug conjugate (ADC) (35)
Approvals (6350)
Artificial intelligence (101)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4382)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (41)
Bladder cancer (18)
Brain cancer (15)
Breast cancer (74)
Cancer (576)
Cardiovascular disease (67)
Career advice (408)
Career pathing (11)
CAR-T (21)
Cell therapy (83)
Cervical cancer (4)
Clinical research (31066)
Collaboration (322)
Compensation (131)
Complete response letters (17)
COVID-19 (758)
CRISPR (19)
C-suite (112)
Cystic fibrosis (35)
Data (591)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1344)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32224)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37767)
Executive appointments (346)
FDA (6701)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (206)
Gene editing (37)
Generative AI (8)
Gene therapy (99)
GLP-1 (339)
Government (1291)
Grass and pollen (2)
Guidances (15)
Healthcare (3637)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (33)
Indications (12)
Infectious disease (789)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (43)
Interviews (59)
IPO (5919)
IRA (29)
Job creations (2061)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (178)
Leadership (3)
Legal (3446)
Liver cancer (19)
Lung cancer (76)
Lymphoma (50)
Machine learning (1)
Management (16)
Manufacturing (145)
MASH (32)
Medical device (1325)
Medtech (1327)
Mergers & acquisitions (9699)
Metabolic disorders (247)
Multiple sclerosis (18)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (547)
NextGen: Class of 2025 (1605)
Non-profit (634)
Northern California (669)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (22)
Pain (49)
Pancreatic cancer (14)
Parkinson's disease (41)
Partnered (7)
Patents (103)
Patient recruitment (28)
Peanut (10)
People (29075)
Pharmaceutical (65)
Pharmacy benefit managers (11)
Phase I (8088)
Phase II (13173)
Phase III (11761)
Pipeline (382)
Podcasts (46)
Policy (58)
Postmarket research (1408)
Preclinical (3238)
Press Release (28)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (156)
Real estate (2666)
Recruiting (17)
Regulatory (10124)
Reports (14)
Research institute (579)
Resumes & cover letters (56)
Rett syndrome (1)
RNA editing (2)
RSV (6)
Schizophrenia (33)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (682)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1650)
State (2)
Stomach cancer (3)
Supply chain (29)
The Weekly (28)
United States (6898)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (49)
Last 7 days (218)
Last 30 days (899)
Last 365 days (12203)
2025 (2923)
2024 (12644)
2023 (14374)
2022 (19732)
2021 (20249)
2020 (19240)
2019 (15132)
2018 (11851)
2017 (13988)
2016 (13239)
2015 (15586)
2014 (12541)
2013 (10657)
2012 (11519)
2011 (12065)
2010 (11025)
Location
Africa (314)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20100)
Australia (2608)
California (1616)
Canada (868)
China (226)
Colorado (65)
Connecticut (65)
Delaware (52)
Europe (39473)
Florida (300)
Georgia (35)
Idaho (9)
Illinois (181)
India (14)
Indiana (129)
Iowa (2)
Japan (85)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (246)
Massachusetts (1393)
Michigan (138)
Minnesota (96)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (709)
New Mexico (7)
New York (470)
North Carolina (378)
North Dakota (3)
Northern California (669)
Ohio (49)
Oklahoma (4)
Oregon (16)
Pennsylvania (407)
Puerto Rico (8)
Rhode Island (7)
South America (503)
South Carolina (2)
Southern California (682)
Tennessee (34)
Texas (216)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (111)
Wisconsin (14)
267,669 Results for "arbor pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene editing
Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’
The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.
March 18, 2025
·
4 min read
·
Dan Samorodnitsky
Press Releases
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics
March 18, 2025
·
4 min read
Business
Sartorius opens new Center of Excellence for bioanalytics in Ann Arbor
The life science group Sartorius opened its new Center of Excellence for bioanalytics in Ann Arbor, Michigan, two years after breaking ground in the Tech Loop at Research Park.
June 6, 2024
·
3 min read
Deals
Arbor Biotechnologies Announces Acquisition of Serendipity
Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.
May 8, 2024
·
3 min read
BioMidwest
Daicel Arbor Biosciences launches new myTXTL® kits to accelerate protein expression
Daicel Arbor Biosciences is excited to announce the release of the next generation of its myTXTL® kits, for cell-free protein expression, designed to simplify and accelerate antibody discovery and protein engineering.
June 25, 2024
·
2 min read
Press Releases
Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1
December 19, 2024
·
3 min read
Business
Allogene, Arbor Team to Develop Off-the-Shelf CAR-T Therapies with CRISPR
Allogene Therapeutics and Arbor Biotechnologies will use their allogeneic CAR T and next-generation gene-editing platforms to develop novel off-the-shelf CAR-T therapies for autoimmune diseases.
March 13, 2024
·
2 min read
·
Tristan Manalac
FDA
Blue Arbor Technologies Receives FDA Breakthrough Device Designation and TAP Enrollment for the RESTORE™ Neuromuscular Interface System
Blue Arbor Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the RESTORE™ Neuromuscular Interface System for people with upper limb loss.
April 24, 2024
·
6 min read
Business
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).
March 12, 2024
·
6 min read
Press Releases
Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 (PH1) and Upcoming Presentations at the 20th Congress of the International Pediatric Nephrology Association (IPNA)
February 5, 2025
·
3 min read
1 of 26,767
Next
